Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
bFtd612TTxwYCTqW